MediWound Earnings Call Balances Setbacks and Expansion

Mediwound ((MDWD)) has held its Q4 earnings call. Read on for the main highlights of the call.

MediWound’s latest earnings call painted a mixed but generally constructive picture for investors, with significant operational advances offset by weak near‑term financials. Management highlighted major milestones in manufacturing scale‑up, late‑stage clinical progress and new partnerships, but also acknowledged revenue declines, wider losses and continued dependence on government funding and regulatory timelines.

Phase III VALUE Trial Progress

The company’s key value driver, EscharEx, continues to advance in the global Phase III VALUE trial targeting 216 patients at about 40 sites in the U.S. and Europe. Management expects a prespecified interim assessment and completion of enrollment by the end of 2026, aiming to preserve roughly 90% statistical power while balancing timelines and spending.

Manufacturing Expansion for NexoBrid

MediWound’s expanded manufacturing facility is now operational and boosts NexoBrid production capacity by a factor of six, a pivotal step for future sales growth and stockpiling demand. Commercial product release from the site, however, still depends on regulatory approvals that are anticipated in 2026, adding an element of timing risk to the growth story.

Strategic Collaborations and Industry Engagement

The company emphasized a growing network of collaborations with leading wound‑care players such as Coloplast/Kerecis, ConvaTec, Essity, Mölnlycke, Solventum and MiMedx. A new partnership with B. Braun around a Phase II study in diabetic foot ulcers further broadens Mediwound’s clinical footprint and may support future market access and indication expansion.

Clinical and Real‑World Evidence Supporting NexoBrid

NexoBrid’s commercial and clinical adoption continues, with use in more than 70 U.S. burn centers, covering most of Vericel’s roughly 90 target sites. Military and real‑world data, including experience from about 5,000 combat casualties and prospective studies in blast injuries, reinforce its utility in severe burns and trauma, potentially underpinning long‑term demand.

Strengthened Cash Position and Financing

The balance sheet exited 2025 in stronger shape, with cash, cash equivalents and deposits rising to $53.6 million from $43.6 million a year earlier, an increase of about 23%. This improvement was driven by a $30 million registered direct offering plus $3.5 million from Series A warrant exercises, providing capital to support ongoing R&D and commercial investments.

Reaffirmed Multiyear Revenue Guidance

Despite recent volatility, management reaffirmed its multiyear revenue outlook, targeting $24 million to $26 million in 2026, $32 million to $35 million in 2027 and $50 million to $55 million in 2028. The 2028 range assumes an initial contribution from EscharEx, alongside continued support from government agencies, suggesting confidence in the long‑term growth trajectory.

Improved Full‑Year Gross Margin

While top‑line trends were soft, profitability metrics showed some underlying improvement, with full‑year 2025 gross profit rising to $3.3 million from $2.6 million in 2024. Gross margin expanded from 13.0% to 19.2%, a gain of 6.2 percentage points, indicating better product economics even as volume and mix faced external headwinds.

Sharp Q4 Revenue Decline

The quarter’s biggest red flag for investors was a steep revenue drop, with Q4 2025 sales falling to $1.9 million from $5.8 million in the prior‑year period, a decline of about 67%. Management attributed most of the shortfall to lower development services revenue tied to the U.S. government shutdown, which delayed budget approvals and new contracts.

Full‑Year Revenue Reduction

For all of 2025, revenue slipped to $17.0 million from $20.2 million in 2024, representing a roughly 16% decline, again largely driven by macro and government‑related factors. Lower product sales to Vericel compounded the pressure, highlighting Mediwound’s current concentration risk and exposure to partner dynamics.

Higher R&D Spend and Increased Operating Losses

Investors are paying for future growth through heavier R&D, with full‑year research and development expenses climbing to $14.0 million from $8.9 million, a surge of about 57%. This spending, mainly for the VALUE Phase III trial, pushed the operating loss to $25.3 million from $19.4 million, while adjusted EBITDA loss widened to $20.3 million from $14.8 million.

Quarterly Profitability Pressure

The fourth quarter underscored short‑term profitability pressure, as net loss grew to $7.2 million, or $0.56 per share, from $3.9 million, or $0.36 per share, an increase of about 85%. Q4 gross profit also slid sharply to $0.3 million with a 14.9% margin, from $0.9 million and a 15.5% margin a year earlier, reflecting the revenue slowdown.

Dependence on Government Contracts and Regulatory Approval

Management was candid that future revenue and manufacturing plans hinge on continued awards from BARDA and the Department of War, as well as timely regulatory clearance of the expanded plant. Because the company does not break out the expected contribution from each source, the precise mix is opaque, and delays in either funding or approvals could materially shift near‑term revenue timing.

Operating Cash Use and Elevated Burn

Underlying cash burn remains elevated despite the bolstered cash balance, with $21.4 million used in operations during 2025 and larger adjusted EBITDA losses. This dynamic underscores the importance of hitting clinical and regulatory milestones on schedule to reduce funding risk and eventually transition toward a more self‑sustaining financial profile.

Forward‑Looking Guidance and Outlook

Looking ahead, Mediwound expects BARDA‑related revenue to begin in the second quarter of 2026 and to be weighted toward the second half as the sixfold‑larger manufacturing site comes online, pending approvals. On the clinical front, the VALUE Phase III design includes an interim sample‑size assessment after about 65% of patients are treated, with potential enrollment increases that could add time and several million dollars but are intended to preserve roughly 90% statistical power.

The call ultimately framed Mediwound as a company in transition, trading near‑term financial pain for potential long‑term gain in burn and wound care. For investors, the story hinges on execution: delivering EscharEx Phase III results, securing government revenues and regulatory clearance for the new plant, and converting today’s collaborations and evidence base into a durable, higher‑margin growth business.